All Stories
Follow
Subscribe to Medigene AG

Medigene AG

ots Ad hoc-Service: MediGene AG <DE0005020903> MEDIGENE'S FIRST PRODUCT CANDIDATE IN PHASE 3 CLINICAL TRIALS

Munich (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
MediGene AG announces the start of a phase 3 trial for Polyphenon
(TM) E to treat genital warts
The German biopharmaceutical company MediGene AG, Munich,
(NMarkt:MDG), announced today that a phase 3 trial for Polyphenon(TM)
E to treat genital warts caused by Human Papilloma Viruses was
initiated in the last week of December 2000. MediGene currently has
three product candidates in clinical trials in- cluding two in
advanced trials: Etomoxir against congestive heart failure in phase 2
and Polyphenon (TM) E against genital warts in phase 3. Internal
development and the planned acquisition of NeuroVir Inc. are to add
another three product candidates in clinical trials to the clinical
pipeline in the first quarter of 2001.
The major aim of the study will be to test the efficacy of two
different formulations of Polyphenon (TM) E for the treatment of
external genital warts. Phase 1 and 2 clinical trials performed for
Polyphenon (TM) E in Canada, the USA and China have demonstrated
safety and a positive trend in efficacy.
Genital warts are tumors caused by the virus strains HPV 6 and HPV
11. The tumors are non-malignant, but disfigure the genital tract and
can be painful. Genital warts are one of the fastest growing sexually
transmitted diseases worldwide. 14 million people in North America
and Europe suffer from the disease, of which only about 3 million are
seeking treatment today.
This ad hoc release contains forward-looking statements that
involve risks and uncertainties. The forward-looking statements
contained herein represent the judgement of MediGene as of the date
of this release. These forward looking statements are no guarantees
for future performance, and the forward-looking events discussed in
this ad hoc release may not occur. MediGene disclaims any intent or
obligation to update any of these forward-looking statements.
For further information please contact:
MediGene AG email:  investor@medigene.de fax: ++49 -89-89 56 32-20
Christine Bohner, Public Relations phone: ++49 - 89 - 89 56 32-16
Michael Nettersheim, Investor Relations phone: ++49 - 89 - 89 56
32-46
End
Internet: http://recherche.newsaktuell.de

Original content of: Medigene AG, transmitted by news aktuell

More stories: Medigene AG
More stories: Medigene AG